Shay Capital LLC Acquires Shares of 4,500 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Shay Capital LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 4,500 shares of the biopharmaceutical company’s stock, valued at approximately $215,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at about $29,000. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC increased its position in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust increased its position in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 322 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 6.3%

Halozyme Therapeutics stock opened at $52.02 on Friday. The company’s 50 day simple moving average is $60.69 and its 200 day simple moving average is $55.90. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51. The firm has a market capitalization of $6.41 billion, a price-to-earnings ratio of 15.17, a PEG ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same quarter last year, the firm earned $0.79 EPS. Halozyme Therapeutics’s quarterly revenue was up 35.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. The trade was a 1.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock valued at $1,276,552 in the last 90 days. 2.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

HALO has been the topic of several recent research reports. Leerink Partnrs lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Leerink Partners lowered shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price on the stock. in a research note on Tuesday. Finally, Morgan Stanley lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $73.00 to $62.00 in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.